Patent intelligence · US
US 7718170
Alkaline phosphatase compositions to reduce skin cancer
Alkaline phosphatase compositions to reduce skin cancer
Patent details — US 7718170
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 18, 2010
- Expiration
- May 13, 2030
- Applicant
- Essential Skincare, LLC
- Claims
- 15
- CPC classes
- A61K, A61K38/40, A61K38/465, A61K38/57
Quick answer
US 7718170 (Alkaline phosphatase compositions to reduce skin cancer) is held by Essential Skincare, LLC. Status: granted. Granted May 18, 2010. Expires May 13, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Essential Skincare, LLC
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K38/40, A61K38/465, A61K38/57, A61K45/06
More from Essential Skincare, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 7718170?
US 7718170 (Alkaline phosphatase compositions to reduce skin cancer) is held by Essential Skincare, LLC. Status: granted. Granted May 18, 2010. Expires May 13, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7718170?
Essential Skincare, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 7718170 expire?
Our index shows an expiration date of May 13, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.